StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
AstraZeneca (AZN) and Merck's (MRK) LYNPARZA Approved in EU for Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer
April 10, 2019 6:46 AM
AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the European Commission has ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
LYNPARZA® (olaparib) Approved in EU for the Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer
April 10, 2019 6:45 AM